| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/07/2001 | WO2001064645A2 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | WO2001064639A2 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | WO2001064637A1 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses |
| 09/07/2001 | WO2001064634A1 Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof |
| 09/07/2001 | WO2001064633A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | WO2001064632A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | WO2001064250A1 Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof |
| 09/07/2001 | WO2001064249A1 Tissue decomposition inhibitor |
| 09/07/2001 | WO2001064235A1 Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d |
| 09/07/2001 | WO2001064230A1 Use of catechin for preventing or treating coronary restenosis |
| 09/07/2001 | WO2001064220A1 Use of trimetazidine to inhibit acyl-coa acetyl transferase |
| 09/07/2001 | WO2001064214A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 09/07/2001 | WO2001064208A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064165A2 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064008A2 Vaccine for the treatment of artherosclerosis |
| 09/07/2001 | WO2001043747A8 Matrix tablet for prolonged release of trimetazidine after oral administration |
| 09/07/2001 | WO2001021761A3 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 09/07/2001 | WO2001019823A3 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/07/2001 | WO2001019780A3 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 09/07/2001 | WO2001016135A3 Reverse-turn mimetics and methods relating thereto |
| 09/07/2001 | WO2001013901A3 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 09/07/2001 | WO2001012812A3 Baff receptor (bcma), an immunoregulatory agent |
| 09/07/2001 | WO2001010841A3 Fluorene derivatives as integrin inhibitors |
| 09/07/2001 | WO2001010423A3 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 09/07/2001 | WO2001010383A3 Caspase inhibitors and uses thereof |
| 09/07/2001 | WO2000078119A3 Cardiomyocytes with enhanced proliferative potential |
| 09/07/2001 | WO2000076528A3 Pharmaceutical preparation containing proteins |
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |
| 09/07/2001 | WO2000062765A3 ESTROGEN RECEPTOR-β LIGANDS |
| 09/07/2001 | WO2000047603A9 16-hydroxyestratrienes as selective estrogens |
| 09/07/2001 | WO2000002912A3 Disintegrin homologs |
| 09/07/2001 | CA2401993A1 Human monoclonal antibodies against oxidized ldl receptor and pharmaceutical uses thereof |
| 09/07/2001 | CA2401834A1 Novel imidazotriazinones and the use thereof |
| 09/07/2001 | CA2401755A1 Vaccine for the treatment of artherosclerosis |
| 09/07/2001 | CA2401697A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | CA2401667A1 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | CA2401665A1 Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d |
| 09/07/2001 | CA2401660A1 Lipid metabolism enzymes |
| 09/07/2001 | CA2401659A1 Il-8 receptor antagonists |
| 09/07/2001 | CA2401621A1 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis |
| 09/07/2001 | CA2401613A1 Amino acids sequencing facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 09/07/2001 | CA2401453A1 G-proteins coupled receptor related polypeptides |
| 09/07/2001 | CA2401357A1 Tissue degradation inhibitor agent |
| 09/07/2001 | CA2401340A1 Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors |
| 09/07/2001 | CA2401175A1 Chordin-like-2 molecules and uses thereof |
| 09/07/2001 | CA2401173A1 G12l, a gene associated with the thermal response |
| 09/07/2001 | CA2400657A1 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | CA2400138A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | CA2400116A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | CA2399704A1 Pyrimidine compounds |
| 09/07/2001 | CA2398685A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/06/2001 | WO2001064715A2 Memno peptides, a process for their preparation and their use |
| 09/06/2001 | US20010020095 High affinity for D4 receptors; treatment of schizophrenia, other psychoses, anxiety disorders, depression, alcohol abuse, impulse control disorders, aggression |
| 09/06/2001 | US20010020042 Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 09/06/2001 | US20010020021 Metalloprotease inhibitor |
| 09/06/2001 | US20010020013 Polymerase inhibitors |
| 09/06/2001 | US20010019724 Carotenoid formulations, comprising a mixture of beta-carotene, lycopene and lutein |
| 09/06/2001 | DE10010067A1 New 2-phenyl-imidazo (5,1-f) (1,2,4) triazin-4-one derivatives, are phosphodiesterase inhibitors useful for treating cardiovascular, cerebrovascular or urogenital disorders |
| 09/06/2001 | DE10006889A1 Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen Use of inhibitors of caspase-3 or caspase-activated deoxyribonuclease (CAD) for the treatment of heart disease |
| 09/05/2001 | EP1130098A2 Mammalian osteoregulins |
| 09/05/2001 | EP1130031A1 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity |
| 09/05/2001 | EP1130027A1 Memno peptides, process for preparation and use thereof |
| 09/05/2001 | EP1130017A2 Azole derivatives and their use as superoxide radical inhibitors |
| 09/05/2001 | EP1129718A2 Therapeutic uses of bactericidal/permeability increasing protein products |
| 09/05/2001 | EP1129715A1 Use of magnesium, calcium and silicon for the healing of different diseases and to the general well-being |
| 09/05/2001 | EP1129711A2 Pinolenic acid against diabetes |
| 09/05/2001 | EP1129350A1 Methods for identifying modulators of bs69 activity |
| 09/05/2001 | EP1129217A2 Compositions and methods of disease diagnosis and therapy |
| 09/05/2001 | EP1129189A2 Human cell surface receptor proteins |
| 09/05/2001 | EP1129181A2 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity |
| 09/05/2001 | EP1129110A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 09/05/2001 | EP1129108A1 Caspases and apoptosis |
| 09/05/2001 | EP1129096A2 Crf receptor antagonists and methods relating thereto |
| 09/05/2001 | EP1129089A1 Spiro-indolines as y5 receptor antagonists |
| 09/05/2001 | EP1129086A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 09/05/2001 | EP1129084A2 Ppar gamma ligands |
| 09/05/2001 | EP1129078A2 Indazole derivatives with 5-ht2 receptor activity |
| 09/05/2001 | EP1129077A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 09/05/2001 | EP1129074A2 Antrhranilic acid amides and the use thereof as medicaments |
| 09/05/2001 | EP1129072A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |
| 09/05/2001 | EP1129068A1 Bicyclic signal transduction inhibitors, composition containing them and uses thereof |
| 09/05/2001 | EP1128837A2 Method for preventing and reversing atherosclerosis in mammals |
| 09/05/2001 | EP1128830A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 09/05/2001 | EP1128826A1 Chromone enteric release formulation |
| 09/05/2001 | EP1128823A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis |
| 09/05/2001 | EP1128816A1 Polyvinyl alcohol microspheres, and methods for making and therapeutic uses of the same |
| 09/05/2001 | EP1128814A1 Aerosols comprising nanoparticle drugs |
| 09/05/2001 | EP1128813A1 An inhalation system |
| 09/05/2001 | EP1128784A1 Therapeutic use of polymers |
| 09/05/2001 | EP1059889A4 Treatment of brain edema using carbonic anhydrase enzyme inhibitor |
| 09/05/2001 | EP0832061B1 Benzamide derivatives and their use as vasopressin antagonists |
| 09/05/2001 | EP0830345B1 Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation |
| 09/05/2001 | EP0777646B1 Metalloproteinase inhibitors |
| 09/05/2001 | EP0699185B1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS |
| 09/05/2001 | CN1311796A Peptide antiangiogenic drugs |
| 09/05/2001 | CN1311785A Tetrahydroquinoline derivatives as glycine antagonists |
| 09/05/2001 | CN1311775A Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 09/05/2001 | CN1311772A New 3-aryl-2-hydoxy-propionic acid derivative I |
| 09/05/2001 | CN1311769A New 3-aryl-2-hydroxypropionic acid derivative III |
| 09/05/2001 | CN1311691A Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody |